An enzyme that normally helps break down stored fats becomes highly active in some cancer cells and makes them more likely to spread, researchers have found.
When the enzyme, called monoacylglycerol lipase (MAGL), goes into overdrive in cancer cells, it breaks down stored fats to produce large amounts of free fatty acids, which are the building blocks of cell membranes and of fatty molecules that serve as signals between cells. These free fatty acids then produce other smaller molecules that promote cancer growth and progression, the study authors noted.
The finding that stored fats in cancer cells can cause them to become more aggressive offers a possible explanation for the reported link between obesity and cancer, according to the researchers at the Scripps Research Institute in California. They also said MAGL may offer a new target for treating aggressive forms of cancer or for preventing cancer progression.
“Historically, research has focused on the mechanisms leading to cancer formation, and therapies have focused on taking out cancer cells. But here we were looking for pathways that lead to cancer aggressiveness,” corresponding author Benjamin Cravatt, chair of the Scripps Research Department of Chemical Physiology, said in a news release.
He noted that people who eat high-fat foods are constantly introducing free fatty acids into their bodies.
“We have shown that cancer cells have their own pathways to produce free fatty acids, which will enable them to become more aggressive. Less malignant cancer cells do not appear to have adopted an autonomous pathway to increase their own pools of free fatty acids. Thus, taking free fatty acids from the diet could assist these cells in developing a more malignant phenotype,” Cravatt said.
The study was published in the Jan. 8 issue of the journal Cell.

To celebrate the arrival of the Christmas & the New Year’s Day and thank for all the people’ s hard work during the passed year, Mr Cai, the CEO of Time-chem, together with the staff hold a warm party, which touched the hearts of all people, enhanced communication among the various departments and encouraged all people to work hard in the future. Furthermore, it’s showed the best cares for all the employees from the leaders.

 

aids

While the war against HIV/AIDS is still far from over, 2009 could prove to be a watershed year in terms of advances in prevention and treatment, experts say.The view on this World AIDS Day, Dec. 1, does seem a bit brighter. In fact, just last month a United Nations report found that the number of people infected with HIV globally has remained unchanged, at about 33 million, for the past two years, and may have peaked in the late 1990s.
Why the change? One big reason could be expanded access to antiretroviral drugs. A report released in October by the World Health Organization, UNICEF and UNAIDS found that 42 percent of people in the developing world who carry HIV now have access to life-extending medications. By the end of 2008, more than 4 million people worldwidewere on antiretroviral medicines — 2.9 million of them in sub-Saharan Africa, where the bulk of HIV-positive people live. That’s a tenfold increase in access over the prior five years.Other nonprofit groups — most notably the Clinton Foundation and the Gates Foundation — have also led the charge, helping to broker price-reduction schemes with pharmaceutical companies for the cheap distribution of AIDS drugs in poorer nations.More widespread access to treatment may also pay dividends in prevention, one expert noted.
In fact, the U.S. Centers for Disease Control and Prevention and the U.S. National Institutes of Health are planning major studies in New York City and Washington, D.C., to see if better identification and treatment of HIV-positive people can help keep infection rates down across the community as a whole.There was also promising news this year in terms of the search for an effective AIDS vaccine.
In October, researchers reporting in the New England Journal of Medicine confirmed that a combination of two vaccines brought about a modest, 31 percent reduction in infection rates among a cohort of 16,000 young adult volunteers in Thailand who were tracked for about three years. Analysis of the trial data suggested that the vaccines’ effect faded with time, however, and was less effective in those at highest risk of HIV, such as sex workers or IV drug abusers.
For these reasons, no one is calling the trial a success. However, the reason that we think it is potentially important is that it’s the first time that we’ve ever seen the slightest positive signal” that immunization against HIV might work.
There were also new glimmers of hope in terms of treatment. One major story was reported as a case study in February in the New England Journal of Medicine. The patient in question was both HIV-positive and had leukemia, and received a stem cell transplant to help cure the cancer. The transplant was unique, however, in that the donor carried a rare gene mutation providing virtual immunity to HIV.
The result: post-transplant, the patient now has no detectable level of HIV in his system.Such a therapy could never become a widespread treatment for HIV/AIDS, because the donor pool is so scarce and bone marrow transplants carry a 30 percent risk of death. But the case does offer intriguing possibilities.It’s a proof of concept that maybe you can cure HIV. So, there’s been interest in finding out where you could do something similar with using gene therapy, bypassing the need for dangerous stem cell transplants.
Other advances in HIV/AIDS made headlines as well in 2009. In February, a topical microbicide gel was found to cut the odds of HIV infection in at-risk African women by 30 percent, while in September researchers at the International AIDS Vaccine Initiative said they’d discovered two immune-system antibodies that might become powerful, broad-spectrum targets for vaccine research in the future.